New Non Invasive Test For Detection Of Tumors Of The Colon Is More Accurate Than Previously Used

New Non Invasive Test For Detection Of Tumors Of The Colon Is More Accurate Than Previously Used.
A recent noninvasive examine to locate pre-cancerous polyps and colon tumors appears to be more accurate than trendy noninvasive tests such as the fecal occult blood test, Mayo clinic researchers say. The scouring for a highly accurate, noninvasive alternative to invasive screens such as colonoscopy or sigmoidoscopy is a "Holy Grail" of colon cancer research medicine. In a preceding trial, the new assess was able to identify 64 percent of pre-cancerous polyps and 85 percent of full-blown cancers, the researchers reported.

Dr Floriano Marchetti, an auxiliary professor of clinical surgery in the division of colon and rectal surgery at University of Miami Sylvester Comprehensive Cancer Center, said the revitalized trial could be an important adjunct to colon cancer screening if it proves itself in further study. "Obviously, these findings poverty to be replicated on a larger scale extenderdeluxeshop.com. Hopefully, this is a good start for a more reliable test".

Dr Durado Brooks, chairman of colorectal cancer at the American Cancer Society, agreed. "These findings are interesting. They will be more enchanting if we ever get this kind of data in a screening population".

The study's lead researcher remained optimistic. "There are 150000 unfledged cases of colon cancer each year in the United States, treated at an estimated price of $14 billion," noted Dr David A Ahlquist, professor of prescription and a consultant in gastroenterology at the Mayo Clinic in Rochester, Minn. "The hallucinate is to eradicate colon cancer altogether and the most realistic approach to getting there is screening. And screening not only in a spirit that would not only detect cancer, but pre-cancer. Our test takes us closer to that dream".

Ahlquist was scheduled to acquaint with the findings of the study Thursday in Philadelphia at a meeting on colorectal cancer sponsored by the American Association for Cancer Research. The young technology, called the Cologuard sDNA test, factory by identifying specific altered DNA in cells shed by pre-cancerous or cancerous polyps into the patient's stool.

If a DNA singularity is found, a colonoscopy would still be needed to confirm the results, just as happens now after a irrefutable fecal occult blood test (FOBT) result. To see whether the test was effective, Ahlquist's line-up tried it out on more than 1100 frozen stool samples from patients with and without colorectal cancer.

The analysis was able to detect 85,3 percent of colorectal cancers and 63,8 percent of polyps bigger than 1 centimeter. Polyps this dimension are considered pre-cancers and most likely to progress to cancer.

The warmth of the test is much better than what has been seen in other stool screening tests, the ACS' Brooks added. "But, showing that in a tight group of samples is very different from demonstrating that in a population where only a small number of individuals are going to have polyps of that size. Then we will grasp if this is a big step forward".

According to Ahlquist, Cologuard is the first noninvasive proof to detect pre-cancerous polyps. In addition, the test is the only one that is able to identify cancer in all locations throughout the colon, something which other tests either can't or don't do well. One more advantage: patients do not requisite to do any loyal preparation before taking the test, something that other tests require.

Ahlquist noted that the test still needs to be refined. "We experienced there are still some bugs and we can make the test even better". Cologuard is not yet available for sale. Clinical trials comparing the assay with colonoscopy are slated to start next year. Ahlquist hopes that the test will be approved and at one's disposal within two years.

Ahlquist noted that the cost of the test has not yet been established. It is expected to set more than a fecal occult blood test, but far less than a colonoscopy. A fecal occult blood prove can cost as little as $23 while a colonoscopy can total $700.

Another benefit is that it would probably need to be done once every three years, while the fecal esoteric blood test is usually done yearly. Savings over time on a more unerring test done fewer times could justify the higher cost of the Cologuard test. In two other presentations at the meeting, researchers have linked frequency gene variants to the risk for colon cancer and also to the prophecy of the disease.

In one study, researchers found that people who have long telomeres, the small strips of DNA that wrap the ends of chromosomes, have a 30 percent increased risk of developing colon cancer. "Even for rank and file their age, their telomeres were longer than you'd expect for healthy people," front researcher Dr Lisa A Boardman, an associate professor of medicine at the Mayo Clinic, said in a statement. "This suggests that there may be two diverse mechanisms that affect telomere measurement and that set up susceptibility to cancer".

In the other study, a research team led by Kim M Smits, a molecular biologist and epidemiologist in the GROW-School for Oncology and Developmental Biology at Maastricht University Medical Center in the Netherlands, uncovered a nonplus when it came to a gene deviating on the KRAS gene called the G variant. This variant, wish linked to poorer outcomes in advanced colorectal cancer, literally predicted a better prognosis in early-stage colon cancer. "You would intuitively think that the G varying would be associated with a poorer prognosis, as it is in late-stage colorectal cancer, but that is not the case," Smits said in a statement expansion. Experts tip out that studies presented at scientific meetings do not have to pass the rigorous peer examination of studies published in reputable journals.